Maryam Ghasemzaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maryam Ghasemzaei has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amir Gholami
Faculty of Medicine, Kurdistan University of Medical Science, Sanandaj 66174-13391, Iran
1 shared publication - Danial Mirzaee
Department of Biology, Faculty of Science, University of Tehran, Tehran, 14155-6455, Iran
1 shared publication - Hubert Bryan Riley
The Center for Energy and Environmental Solutions (CEES), College of STEM-T, South Carolina State University, Orangeburg, SC 29117, USA
1 shared publication - Iraj Alipourfard
Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Majid Farsadrooh
Renewable Energies Research Laboratory, Department of Chemistry, Faculty of Science, University of Sistan and Baluchestan, P.O. Box 98135 674, Zahedan, Iran
1 shared publication - Marzieh Ramezani Farani
NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1552
Multifunctional Nano-Contrast Agent Carriers: From Traditional Platforms to Next-Generation Theranostic Applications in Molecular Imaging
Multifunctional nano-contrast agent carriers are redefining molecular imaging by combining high-fidelity visualization with targeted delivery, controlled release, and, increasingly, therapeutic action. This review encompasses the development of nano-contrast platforms from conventional dendrimer, liposome, chitosan, and silica systems to modular nano-contrast platforms for multimodal, multi-parametric, and activatable imaging in clinically relevant environments. We dissect engineering strategies that govern surface chemistry, ligand organization, stimulus responsiveness, and microenvironmental sensing, and relate them to theranostic performance, immune system engagement, and quantitative image readouts. Biodistribution, pharmacokinetics, and safety are discussed from both classical and model-informed perspectives, with design principles that favor predictable behavior, manufacturability, and regulatory acceptance. Current clinical translation, regulatory pathway evolution, and market dynamics are critically reviewed to elucidate that a few nano-contrast agents have reached patients despite a widespread experimental landscape. Finally, we discuss emerging trends, including biomimetic and ultrasmall carriers, metal–organic and hybrid frameworks, AI-assisted design, digital twins, and precision medicine workflows, which are likely to shape the next-generation nano-contrast theranostics. By systematically relating material selection and carrier architecture to imaging function and translational limitations, this review suggests concrete research priorities for taking nano-contrast agents from sophisticated prototypes to robust, patient-tailored tools.
- 10 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1552
Open AccessMultifunctional Nano-Contrast Agent Carriers: From Traditional Platforms to Next-Generation Theranostic Applications in Molecular Imaging
Multifunctional nano-contrast agent carriers are redefining molecular imaging by combining high-fidelity visualization with targeted delivery, controlled release, and, increasingly, therapeutic action. This review encompasses the development of nano-contrast platforms from conventional dendrimer, liposome, chitosan, and silica systems to modular nano-contrast platforms for multimodal, multi-parametric, and activatable imaging in clinically relevant environments. We dissect engineering strategies that govern surface chemistry, ligand organization, stimulus responsiveness, and microenvironmental sensing, and relate them to theranostic performance, immune system engagement, and quantitative image readouts. Biodistribution, pharmacokinetics, and safety are discussed from both classical and model-informed perspectives, with design principles that favor predictable behavior, manufacturability, and regulatory acceptance. Current clinical translation, regulatory pathway evolution, and market dynamics are critically reviewed to elucidate that a few nano-contrast agents have reached patients despite a widespread experimental landscape. Finally, we discuss emerging trends, including biomimetic and ultrasmall carriers, metal–organic and hybrid frameworks, AI-assisted design, digital twins, and precision medicine workflows, which are likely to shape the next-generation nano-contrast theranostics. By systematically relating material selection and carrier architecture to imaging function and translational limitations, this review suggests concrete research priorities for taking nano-contrast agents from sophisticated prototypes to robust, patient-tailored tools.